Format

Send to

Choose Destination
See comment in PubMed Commons below
Acta Med Okayama. 2007 Dec;61(6):341-4.

Routine transurethral biopsy of the bladder is not necessary to evaluate the response to bacillus calmette-guerin therapy.

Author information

1
Department of Urology, Himeji St. Mary's Hospital, Himeji, Hyogo 670-0801, Japan.

Abstract

We evaluated the need for transurethral biopsy at first follow-up after intravesical bacillus Calmette-Guerin (BCG) therapy for superficial bladder cancer. The records of 84 patients with superficial bladder cancer who received a 6- or 8-week course of BCG were reviewed. Pathological results before BCG, cystoscopic findings, urinary cytology, and biopsy results for evaluation of BCG therapy were reviewed. All 19 patients with positive urinary cytology had evidence of positive bladder biopsy results. Fifty-three of 54 patients (98.1%) with no visible recurrent tumor and negative urinary cytology demonstrated negative pathological results on bladder biopsy. When not found in conjunction with positive urinary cytology, erythematous mucosa on cystoscopy was not an indicator of tumor recurrence or residual cancer. In conclusion, routine transurethral biopsy of the bladder for evaluating the response to BCG intravesical therapy is not necessary in patients who have no visible tumor on cystoscopy and negative urinary cytology.

PMID:
18183079
DOI:
10.18926/AMO/32881
[Indexed for MEDLINE]
Free full text
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Okayama University Medical School
    Loading ...
    Support Center